US-based firm Eco Petroleum Solutions has completed the acquisition of drug development company Immunotech Laboratories in a share exchange transaction.

Immunotech Laboratories specialises in the commercialisation of its proprietary proteins to treat patients affected with debilitating infectious diseases.

Under the deal, the company is committed to develop drugs to ensure the better health of human beings and for the realisation of shareholder value for the existing shareholder groups of the two companies.

The major Immunotech compound ITV-1 is a suspension of inactivated pepsin fragment (IPF), which, according to studies conducted, is believed to be effective in the treatment of HIV.

IPF is the active drug substance of ITV-1 and a purified extract of porcine pepsin.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The major Immunotech compound ITV-1 is a suspension of inactivated pepsin fragment (IPF), which, according to studies conducted, is believed to be effective in the treatment of HIV."

ITV-1 has revealed capability of modulating the immune system, as well as successfully completed its Phase I, II and III clinical trials in Sophia, Bulgaria, through Immunotech Laboratories BG – Europe, a subsidiary of the acquired organisation.

See Also:

The final report of the Phase III trial was performed on a test group of salvage patients suffering from HIV / AIDS, and showed that improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK and of the index CD4/CD8 decreased in the viral load.

It also demonstrated a good treatment effect on opportunistic infections, compatibility with all of the other modern antiretroviral drugs and exceptional tolerance in all patients with a complete lack of any major side effects.

The validation of treatment manufacturing produced by a US contract manufacturer is currently in process.